



UNITED STATE LEPARTMENT OF COMMERC

Patent and Trademark Offic

COMMISSIONER OF PATE Washington: O.C., 20231 AND TRADEMARKS

APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. US/842.408 05/03/98 PIETN | PIETN |

EPI GOODET

APRIL C LOGAN
THE SCRIPPS RESEARCH INSTITUTE
OFFICE OF PATENT COUNSEL
10550 NORTH TORREY PINES ROAD
LA JELAA CA 92037

OCICETED ART UNIT PAPER

11/25/97

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademark

EXHIBIT B

Office Action Summary	Application No.	Applicant(8)		
	08/642.406 Examiner		Group Art Unit	
	Thomas Haas		1803	
Responsive to communication(s) filed on			·	'
☐ This action is FINAL,			3	
Since this application is in condition for allowance exce in accordance with the practice under Ex parte Quayle,			on as to the me	rits is closed
A shortened statutory period for response to this action is is longer, from the mailing date of this communication. Fa application to become abandoned. (35 U.S.C. § 133). Ex 37 CFR 1.136(a).	ilure to respond withi	n the period	d for response v	will cause the
Disposition of Claims	•		* "	
X Claim(s) 1-20		is/are	pending in the a	application.
Of the above, claim(s)-13-20	· · · · · · · · · · · · · · · · · · ·	is/are w	ithdrawn from	consideration.
Claim(s)	*	Is	a/are allowed.	-
		is	/are rejected.	
Claim(s)	· · · · · · · · · · · · · · · · · · ·	la la	lare objected to	o.
☐ Claims	are subject	to restricti	ion or election i	equirement.
Application Papers See the attached Notice of Draftsperson's Patent Draftsperson Draftsperso	swing Barjaw, PTA-9	A B		
The drawing(s) filed onis/are o	•			
☐ The proposed drawing correction, filed on			disapproved.	
☐ The specification is objected to by the Examiner.			1	
☐ The oath or declaration is objected to by the Examina	er.			
Priority under 35 U.S.C. § 119				
Acknowledgement is made of a claim for foreign price	orlty under 35 U.S.C.	§ 119(a)-(d	d).	
☐ All ☐ Some* ☐ None of the CERTIFIED cop	es of the priority doc	uments hav	re been	
received.				
☐ received in Application No. (Series Code/Serial ☐ received in this national stage application from				
*Certified copies not received:			iule 17.2(3)).	
☐ Acknowledgement is made of a claim for domestic p			195	 ·
Attachment(s)				
Notice of References Cited, PTO-892				
☑ Information Disclosure Statement(s), PTO-1449, Pap ☐ Interview Summary, PTO-413	er No(s) <u>5</u>			
☑ Notice of Draftsperson's Patent Drawing Review, PT	O-948			
☐ Notice of Informal Patent Application, PTO-152				
			,	
·				
SEE DESICE ACTION	ON THE FOLLOWING S	ACES _		

Serial Number: 08/642,406

Page 2

Art Unit: 1803

DETAILED ACTION

Drawings

1. The drawings are objected to for the reasons cited on form PTO 948. Correction is required.

Double Patenting

2. The non-statutory double patenting rejection, whether of the obviousness-type or non-obviousness-type, is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent. In re Thortngton, 418 F.2d 528, 163 USPQ 644 (CCPA 1969); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); and In re Goodman, 29 USPQ2d 2010 (Fed. Cir. 1993).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(b) and (c) may be used to overcome an actual or provisional rejection based on a non-stautory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.78(d).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

3. Claims 1-12 are rejected under the judicially created doctrine of obviousness-type double patenting as being unparentable over claims 1-11 of U.S. Patent No. 5,639,947. Although the conflicting claims are not identical, they are not patentably distinct from each other because the transgenic plant and method of making same as defined by claims 1-12 of the instant application

6. 2004 8: 24PM Scripps Rosedien Institute Under LARDNER

Serial Number: 08/642,406

Art Unit: 1803

Page 3

are encompassed by claims 1-11 of U.S. Patent No. 5,639,947. One of ordinary skill in the art would recognize that the number of plants trassformed with the particular nucleotide sequences of the invention is an optimization of design parameters as these plants are to be sexually crossed and selected and thereby the resulting transgenic plants would comprise the desired heterologous nucleotide sequences.

Conclusion

4. No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Thomas Haas whose telephone number is (703) 305-7270. The examiner can normally be reached on Mon.-Fri. from 7:00 to 4:30.

If anemors to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Doug Robinson, can be reached on (703) 308-2897. The fax phone number for this Group is (703) 305-3014.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.